[CANF] Can-Fite Biopharma Ltd


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 30.92 M

Exchange: AMEX

The data is delayed by 15 minutes.


Price: 2.42 Change: -0.01 (-0.41%)
Ext. hours: Change: 0 (0%)

chart CANF

Refresh chart

Description: Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding13.74 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow-4.27 ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week20.25 Low 52 week1.16 Last close5.15 Last change-9.01%
RSI14.02 Average true range3.86 Beta0.03 Volume40.22 K
Simple moving average 20 days-23.55% Simple moving average 50 days-51.04% Simple moving average 200 days-36.41%
Performance Data
Performance Week-20.65% Performance Month-32.67% Performance Quart-70.01% Performance Half273.19%
Performance Year293.13% Performance Year-to-date-72.75% Volatility daily5.91% Volatility weekly13.22%
Volatility monthly27.09% Volatility yearly93.85% Relative Volume163.54% Average Volume396.1 K
New High New Low


2019-11-11 09:51:54 | Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals

2019-11-11 07:00:00 | Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market

2019-11-04 07:00:00 | Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients

2019-10-31 07:00:00 | U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer

2019-10-17 08:00:00 | Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis

2019-10-16 07:00:00 | Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report

2019-10-15 06:30:00 | Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™

2019-10-10 07:00:00 | Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine

2019-09-23 07:00:00 |  Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference

2019-09-11 13:16:23 | A Look At Benzinga Pro's Most-Searched Tickers For September 11, 2019

2019-09-10 08:10:00 | Can-Fite's stock soars on heavy volume after collaboration deal with cannabis company Univo

2019-09-10 06:03:00 | Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

2019-09-10 05:38:00 | Can-Fite Shares Surge on Univo Accord to Develop Cannabis-Based Therapeutics

2019-08-29 07:00:00 | Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update

2019-08-06 07:00:00 | Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel

2019-08-01 09:38:22 | Can-Fite BioPharma Reports $4M Deal With Kyongbo Pharm

2019-07-10 09:56:12 | Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

2019-06-20 09:00:01 | All You Need to Know About Can-Fite CANF Rating Upgrade to Strong Buy

2019-06-04 07:00:00 | Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019

2019-06-03 07:00:00 | Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session

2019-05-29 07:00:00 | Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update

2019-05-24 13:46:45 | Secondary Offerings Put A Pause On May's Momentum

2019-05-23 07:00:00 | The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin

2019-05-20 14:06:11 | Can-Fite BioPharma Announces $6 Million Registered Direct Offering

2019-05-20 11:52:36 | Can-Fite Abstract Selected For Liver Conference

2019-05-20 07:00:00 | Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum ILCA

2019-05-06 07:00:00 | Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson

2019-05-01 16:05:00 | Can-Fite Announces ADS Ratio Change

2019-04-15 07:00:00 | Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea

2019-04-10 07:07:00 | Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology ASCO Annual Meeting

2019-04-02 09:00:00 | Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

2019-03-29 16:30:00 | Can-Fite Files Annual Report for the Year Ended December 31, 2018

2019-03-28 07:00:00 | Can-Fite Reports 2018 Financial Results & Provides Clinical Update

2019-03-26 07:00:00 | Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

2019-03-20 14:15:00 | Four Marijuana Stocks on the Rise on Wednesday

2019-02-27 07:00:00 | Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo

2019-02-25 07:00:00 | Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication

2019-02-04 09:30:00 | Watch These 4 Healthcare Stocks Set The Pace On Monday 2/4/19

2019-02-04 07:00:00 | Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug

2019-01-30 09:35:00 | 4 Healthcare Stocks Raising The Bar On Wednesday 1/30/19

2019-01-30 07:00:00 | Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

2019-01-24 07:30:00 | Can-Fite BioPharma CEO Letter to Shareholders

2019-01-18 08:00:00 | Can-Fite BioPharma Announces Registered Direct Offering

2019-01-08 08:00:00 | Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent

2019-01-03 08:02:00 | Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference

2018-12-10 07:00:00 | Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC

2018-11-30 07:00:00 | Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update

2018-11-20 07:00:00 | Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert

2018-10-31 07:00:00 | Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

2018-10-25 07:00:00 | Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference